ENDLOS-TURBO PUT - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 13:04:34 2024-07-05 EDT | ||
| 5.51 EUR | -5.00% |
|
| Current month | -2.19% | ||
| 1 month | +6.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 5.51 | -5.00% |
| 24-07-04 | 5.8 | -6.00% |
| 24-07-03 | 6.17 | +9.40% |
| 24-07-02 | 5.64 | -3.92% |
| 24-07-01 | 5.87 | -1.01% |
Real-time Boerse Frankfurt Warrants
Last update July 05, 2024 at 01:04 pm
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | DZ BANK |
| WKN | DJ7M8G |
| ISIN | DE000DJ7M8G8 |
| Date issued | 2023-12-15 |
| Strike | 533.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 11.22 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.4 € |
|---|---|
| Lowest since issue | 4.38 € |
| Spread | 0.03 € |
| Spread % | 0.54% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Certificates
- Certificat
